IVERIC bio, Inc. (ISEE)

IVERIC bio, Inc. (ISEE) Gesundheitswesen & Pipeline-Uebersicht

IVERIC bio is pioneering innovative therapies for retinal diseases, with a focus on geographic atrophy (GA) and inherited retinal diseases (IRDs). Their lead asset, Zimura, addresses a significant unmet need in dry age-related macular degeneration, positioning IVERIC bio for substantial growth in the ophthalmology market.

Investmentthese

IVERIC bio presents a notable research candidate due to its focus on addressing significant unmet needs in the retinal disease market. The company's lead asset, Zimura, has the potential to become a leading treatment for geographic atrophy (GA), a major cause of vision loss in the elderly. Positive data from the GATHER trials could drive significant value appreciation. The company's pipeline of product candidates targeting other retinal diseases, such as LCA10 and STGD1, provides further growth potential. With a market capitalization of $5.51 billion and a beta of 1.10, IVERIC bio offers a blend of growth and moderate volatility. Successful commercialization of Zimura and advancement of its pipeline programs are key value drivers.

Basierend auf FMP-Finanzdaten und quantitativer Analyse

Wichtige Highlights

• Market capitalization of $5.51 billion reflects investor confidence in IVERIC bio's pipeline and potential.
• Zimura, the lead product candidate, targets geographic atrophy (GA), a significant unmet medical need in dry age-related macular degeneration (AMD).
• Completion of Phase 2/3 clinical trial (GATHER1) and ongoing Phase 3 clinical trial (GATHER2) for Zimura indicate progress towards potential regulatory approval.
• Pipeline includes product candidates targeting orphan inherited retinal diseases (IRDs), offering diversification and long-term growth potential.
• The company changed its name to IVERIC bio, Inc. in April 2019, signaling a strategic shift and renewed focus on retinal disease therapies.

Wettbewerber & Vergleichsunternehmen

Staerken

• Novel therapies targeting unmet needs in retinal diseases.
• Lead product candidate, Zimura, in late-stage clinical development.
• Pipeline of product candidates targeting various retinal diseases.
• Expertise in complement inhibition and retinal disease biology.

Schwaechen

• Reliance on successful clinical trial outcomes and regulatory approvals.
• High research and development costs.
• Competition from established pharmaceutical companies.
• Negative P/E ratio of -27.51 indicates current unprofitability.

Katalysatoren

• Upcoming: Data readout from the GATHER2 Phase 3 clinical trial for Zimura in geographic atrophy (GA).
• Upcoming: Regulatory submission for Zimura to health authorities.
• Ongoing: Enrollment and progress in the Phase 2b clinical trial for STAR (OPH2005) in LCA10 and STGD1.
• Ongoing: Advancement of IC-500, IC-100, and IC-200 programs through preclinical and clinical development.
• Ongoing: Potential strategic partnerships or acquisitions to expand pipeline and capabilities.

Risiken

• Potential: Clinical trial failures or delays for Zimura or other product candidates.
• Potential: Regulatory setbacks or rejection of product candidates by health authorities.
• Ongoing: Competition from established pharmaceutical companies and new therapies.
• Potential: Patent challenges or loss of exclusivity for key products.
• Ongoing: High research and development costs and potential need for additional financing.

Wachstumschancen

• Zimura for Geographic Atrophy (GA): The primary growth driver is the potential approval and commercialization of Zimura for GA secondary to dry AMD. The GA market represents a multi-billion dollar opportunity, with a significant unmet need for effective treatments. Successful completion of the GATHER2 trial and subsequent regulatory approval could lead to rapid market penetration and substantial revenue growth. Timeline: Potential approval within the next 1-2 years.
• STAR (OPH2005) for LCA10 and STGD1: IVERIC bio's STAR program targets Leber congenital amaurosis type 10 (LCA10) and autosomal recessive Stargardt disease (STGD1), both orphan inherited retinal diseases. These diseases have limited or no approved treatments, presenting a significant market opportunity for novel therapies. Positive data from the Phase 2b clinical trial could accelerate development and lead to regulatory approval. Timeline: Potential approval within the next 3-5 years.
• IC-500 for GA and other Age-Related Retinal Diseases: IC-500, a high temperature requirement A serine peptidase 1 protein inhibitor, targets GA and other age-related retinal diseases. This program expands IVERIC bio's pipeline and diversifies its approach to treating AMD. Successful preclinical and clinical development could lead to a valuable addition to the company's portfolio. Timeline: Potential approval within the next 5-7 years.
• Expansion into Additional Retinal Diseases: IVERIC bio has ongoing discovery and research programs targeting other retinal diseases, including miniCEP290, miniABCA4, and miniUSH2A programs for LCA10, STGD1, and Usher syndrome type 2A-Related IRDs, respectively. These programs represent long-term growth opportunities and could lead to the development of new therapies for underserved patient populations. Timeline: Potential approval within the next 7-10 years.
• Strategic Partnerships and Acquisitions: IVERIC bio could pursue strategic partnerships or acquisitions to expand its pipeline, access new technologies, or accelerate commercialization efforts. These transactions could provide additional growth opportunities and enhance the company's competitive position in the ophthalmology market. Timeline: Ongoing.

Chancen

• Growing prevalence of age-related macular degeneration (AMD).
• Increasing awareness and diagnosis of inherited retinal diseases (IRDs).
• Potential for strategic partnerships and acquisitions.
• Expansion into new geographic markets.

Risiken

• Clinical trial failures or delays.
• Regulatory setbacks or rejection of product candidates.
• Competition from new therapies and technologies.
• Patent challenges or loss of exclusivity.

Wettbewerbsvorteile

• Patented technologies and intellectual property protecting its product candidates.
• Clinical trial data demonstrating the safety and efficacy of its therapies.
• Expertise in retinal disease biology and drug development.
• Orphan drug designations providing market exclusivity for certain products.

Ueber ISEE

IVERIC bio, Inc., formerly known as Ophthotech Corporation, was founded in 2007 and is headquartered in Parsippany, New Jersey. The company is dedicated to the discovery and development of novel treatments for retinal diseases, with a particular emphasis on age-related macular degeneration (AMD) and orphan inherited retinal diseases (IRDs). IVERIC bio's lead product candidate is Zimura, an inhibitor of complement factor C5. Zimura is being developed for the treatment of geographic atrophy (GA) secondary to dry AMD, a condition with limited treatment options. The GATHER1 Phase 2/3 clinical trial for Zimura has been completed, and the GATHER2 Phase 3 clinical trial is underway. Beyond Zimura, IVERIC bio has a pipeline of product candidates targeting various retinal diseases, including STAR or OPH2005 for Leber congenital amaurosis type 10 (LCA10) and autosomal recessive Stargardt disease (STGD1), as well as IC-500, IC-100, and IC-200 for other forms of GA and IRDs. The company's research programs also include miniCEP290, miniABCA4, and miniUSH2A programs for LCA10, STGD1, and Usher syndrome type 2A-Related IRDs, respectively. IVERIC bio operates as a biopharmaceutical company, focusing on research, development, and potential commercialization of its pipeline products in the ophthalmology space.

Was das Unternehmen tut

• Discovers and develops novel treatments for retinal diseases.
• Focuses on age-related macular degeneration (AMD) and inherited retinal diseases (IRDs).
• Develops Zimura, an inhibitor of complement factor C5, for geographic atrophy (GA).
• Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
• Develops STAR (OPH2005) for Leber congenital amaurosis type 10 (LCA10) and autosomal recessive Stargardt disease (STGD1).
• Researches and develops IC-500, IC-100, and IC-200 for various retinal diseases.
• Engages in discovery and research programs for miniCEP290, miniABCA4, and miniUSH2A programs.

Geschaeftsmodell

• Develops and patents novel therapies for retinal diseases.
• Conducts clinical trials to obtain regulatory approval from health authorities.
• Potentially commercializes approved products through its own sales force or partnerships.
• Out-licenses or sells its technologies or products to other pharmaceutical companies.

Branchenkontext

IVERIC bio operates in the biotechnology industry, specifically targeting the ophthalmology market. The retinal disease market is characterized by a growing prevalence of age-related macular degeneration (AMD) and inherited retinal diseases (IRDs), driven by an aging population and advancements in genetic diagnostics. The competitive landscape includes companies such as ABCM, ALPN, CBAY, CERE, and LHCG, as well as larger pharmaceutical companies with ophthalmology divisions. IVERIC bio aims to differentiate itself through its focus on complement inhibition and its pipeline of novel therapies for underserved retinal diseases.

Wichtige Kunden

• Patients with age-related macular degeneration (AMD).
• Patients with inherited retinal diseases (IRDs).
• Ophthalmologists and retina specialists.
• Hospitals and clinics.

Finanzdaten

Chart & Info

Aktuelle Nachrichten

Analystenkonsens

MoonshotScore

ISEE Healthcare Aktien-FAQ

Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.

Offizielle Ressourcen

Popular Stocks